Description
Rezurock (belumosudil) is a medication used to treat adult patients with chronic graft-versus-host disease (GVHD) after at least two previous treatments have failed. Rezurock is a small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2) and is administered orally.
Uses:
Rezurock is used to treat adult patients with chronic GVHD, a condition that occurs after a transplant when the new cells from the donor attack the recipient’s body. Chronic GVHD affects many organs and can lead to serious health problems. Rezurock works by inhibiting ROCK2, a protein that plays a role in the immune response, and reducing inflammation in the affected organs.
Storage Conditions:
Rezurock should be stored at room temperature between 68°F and 77°F (20°C and 25°C) in its original container. The medication should be protected from light and moisture.
Mechanism of Action:
Rezurock works by inhibiting ROCK2, a protein that plays a role in the immune response. In patients with chronic GVHD, the immune system attacks the recipient’s organs, causing inflammation and damage. By inhibiting ROCK2, Rezurock reduces inflammation in the affected organs and may improve symptoms of chronic GVHD.
How to Use:
Rezurock is taken orally twice daily with or without food. The dosage and duration of treatment are determined by the healthcare provider based on the patient’s weight and kidney function. The recommended starting dose is 200 mg twice daily.
Precautions:
Before taking Rezurock, patients should inform their healthcare providers of any allergies, medical conditions, and medications they are currently taking. Rezurock may increase the risk of infections and certain types of cancer, and patients should be monitored for signs of infection and regularly screened for cancer. The medication may also cause liver function abnormalities, and patients should be monitored regularly for liver function.
Drug Interactions:
Rezurock may interact with drugs that affect the liver or are metabolized by the liver. Patients should inform their healthcare providers of any medications they are taking, including over-the-counter medications, vitamins, and supplements, before taking Rezurock.
Contraindications:
Rezurock is contraindicated in patients with a known hypersensitivity to belumosudil or any of its components. It should not be used in patients with severe liver impairment or in combination with certain medications.
Overdose:
In the event of an overdose, patients should contact their healthcare provider. Symptoms of an overdose may include fatigue, headache, nausea, and vomiting.
Adverse Reactions:
The most common adverse reactions reported with Rezurock include infections, diarrhea, abdominal pain, and rash. Patients should report any adverse reactions to their healthcare provider.
Overall, Rezurock is a small molecule inhibitor of ROCK2 used to treat adult patients with chronic GVHD after at least two previous treatments have failed. The medication is taken twice daily with or without food, and the dosage and duration of treatment are determined based on the patient’s weight and kidney function. Patients should inform their healthcare provider of any allergies, medical conditions, and medications they are taking and should be monitored regularly for signs of infection, cancer, and liver function abnormalities. Rezurock may cause adverse reactions such as infections, diarrhea, abdominal pain, and rash and is contraindicated in some patients.
Reviews
There are no reviews yet.